A U.S. federal judge rejected Swiss drugmaker Novartis' request for a preliminary injunction to stop MSN Pharmaceuticals from ...

Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug ...

Novartis could soon face generic competition for Entresto after judge's ruling.

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

Novartis AG (NVS) reports robust sales and income growth, announces a $10 billion share buyback, and navigates competitive ...

The pharmaceutical company raised its full-year profit guidance as ongoing demand for key drugs fueled growth in ...

NVS beats on Q2 earnings, raises 2025 income outlook on strong drug sales, but Cosentyx miss and CFO exit weigh on shares.

The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” ...

Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...

Divi's Labs makes active pharmaceutical ingredients for Entresto for Novartis, which contributes nearly 8% to Hyderabad-based ...

Novartis (NVS) stock slips as the company lost its bid to block MSN Pharma's generic Entresto launch after a U.S. judge ruled against its injunction. Read more here.